Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

Molecular Residual Disease study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators SALT LAKE CITY, May 23, 2024 -- Myriad Genetics, Inc., , a leader...

Related Keywords

Japan ,Texas ,United States ,Salt Lake City ,Utah ,Matt Scalo ,George Daneker Jr ,Bracanalysis Cdx ,Hollyj Pederson ,Glenn Farrell ,Exchange Commission ,A Myriad Collaborative Research Registry Study ,Genetics Inc ,Breast Services ,University Of Texas Md Anderson Cancer Center ,Collaborative Research Registry ,National Cancer Center Hospital ,Memorial Sloan Kettering Cancer Center ,Nasdaq ,Oncology Solutions ,Molecular Residual Disease ,Diagnostic Test ,Myriad Collaborative Research Registry ,Medical Breast Services ,Germline Genetic Profiles ,Ovarian Malignancies ,Myriad Collaborative Research Registry Study ,Uterine Cancer ,Hereditary Cancer Test ,Tumor Test ,Prostate Cancer Prognostic Test ,Breast Cancer Prognostic Test ,Folate Receptor Alpha ,Germline Companion Diagnostic ,Cancer Center ,National Cancer Center Hospital East ,Intermountain Precision Genomic ,Precise Tumor ,Precise Liquid ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,